<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01903798</url>
  </required_header>
  <id_info>
    <org_study_id>SCAHC Clinical Trial</org_study_id>
    <secondary_id>1U01AA021886</secondary_id>
    <nct_id>NCT01903798</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Mycophenolate Mofetil and Rilonacept in Patients With Alcoholic Hepatitis</brief_title>
  <official_title>A Phase II, Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of Mycophenolate Mofetil and Rilonacept (Anti-interleukin-1) in Patients With Alcoholic Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern California Institute for Research and Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VA Long Beach Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Southern California Institute for Research and Education</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial will test two new therapies for the treatment of alcoholic hepatitis.
      Patients who &quot;respond&quot; to the current standard of care therapy for alcoholic
      hepatitis(corticosteroid/prednisolone therapy) after 1 week of treatment will be randomly
      assigned to either continue on standard therapy, or, to begin treatment with rilonacept in
      combination with standard therapy. Patients who are &quot;non-responders&quot; to the current standard
      of care therapy after 1 week of treatment will be randomly assigned to standard of care or to
      begin treatment with mycophenolate mofetil in combination with standard therapy. Patients
      will be treated for a total of 4 weeks in this clinical trial. Patients will be followed for
      up to five months after completing therapy (6 months total).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized trial of two experimental treatments, prednisolone +
      mycophenolate mofetil and prednisolone + rilonacept, in comparison with standard of care, in
      patients with alcoholic hepatitis. Patients will start therapy with prednisolone. At Day 8
      response to prednisolone will be determined using the Lille score. Patients with a Lille
      score ≥ 0.45 will be randomized to standard of care (continue prednisolone, stop all therapy
      and/or offer palliative care) or to have prednisolone continued and mycophenolate added for
      the next three weeks. Patients with a Lille score &lt;0.45 will be randomized to continue
      prednisolone alone (standard of care) or to have rilonacept added to their treatment regimen
      (experimental group) for the next three weeks. Patients will complete follow-up visits at
      Week 12 and Week 24.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival at Day 29 of the Assigned Treatment</measure>
    <time_frame>Day 8 to Day 29</time_frame>
    <description>To determine whether treatment with prednisolone + mycophenolate mofetil is better than standard of care treatment among patients with alcoholic hepatitis who fail to respond to 1 week of prednisolone (i.e., Lille score of ≥0.45). Primary outcome is survival at Day 29.
All study participants received the Standard of care (prednisolone) with or without experimental drug at Day 1 (based on randomization). Response to the treatment was determined at Day 8. Data was collected for both responders and non-responders.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Reported Ascites</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>Prednisolone (Lille &lt;0.45)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At Day 8, after randomization, this participants will continue prednisolone 40 mg/day (current standard of care) for 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone, rilonacept (Lille &lt;0.45)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will continue Prednisolone (40mg/day). Additionally, they will receive rilonacept (Arcalyst®) once a week for 21 days. After randomization at Day 8, study participants will be given 320 mg subcutaneously (two injections of 2.0 ml, 160 mg each). On Day 15 and Day 22, study participants will be given 160 mg subcutaneously (one injection of 160 mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone (Lille &gt;0.45)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisolone (40 mg/day) for the first 7 days, after randomization at Day 8, they will stop all therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone, mycophenolate(Lille &lt;0.45)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will continue Prednisolone (40mg/day). Additionally, they will receive mycophenolate mofetil (CellCept®) for a total of 21 days. After randomization at Day 8, they will receive CellCept® at a dose of 1000 mg per day for the first four days followed by 2000 mg per day (two 500 mg tablets bid) for the remaining 17 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Immunosuppressive agent</description>
    <arm_group_label>Prednisolone, mycophenolate(Lille &lt;0.45)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Corticosteroid</description>
    <arm_group_label>Prednisolone (Lille &lt;0.45)</arm_group_label>
    <arm_group_label>Prednisolone (Lille &gt;0.45)</arm_group_label>
    <arm_group_label>Prednisolone, mycophenolate(Lille &lt;0.45)</arm_group_label>
    <arm_group_label>Prednisolone, rilonacept (Lille &lt;0.45)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rilonacept</intervention_name>
    <arm_group_label>Prednisolone, rilonacept (Lille &lt;0.45)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of chronic alcohol consumption (defined as &gt;60g ethanol/day for women and &gt;80g
             ethanol/day for men) for at least the past 5 years

          -  Less than 8 weeks between last intake of alcohol and Screening

          -  Maddrey's Discriminant Function score (DF)&gt;32

          -  Willing to undergo liver biopsy for histological assessment of alcoholic hepatitis.

          -  Willing to provide liver tissue, whole blood, stool and ascitic fluid as part of a
             correlative study

          -  Onset of jaundice &lt;3 months prior to Screening

          -  Age greater or equal to 18 years

        Exclusion Criteria (Brief):

          -  Liver disease significantly caused by etiologies other than alcohol.

          -  Upper GI bleeding requiring transfusion within 48 hours prior to start of prednisolone
             (Day 1)

          -  Infection that has been treated with appropriate antibiotics for less than 72 hours or
             which has not responded appropriately to 72 hours or more of antibiotic treatment
             prior to start of prednisolone (Day 1)

          -  Clinical evidence of select active infections in the past 3 months (fungal,
             mycobacterial, cytomegalovirus (CMV), herpes, coccidioidomycosis, tuberculosis (TB)
             and human immunodeficiency virus (HIV))

          -  Renal insufficiency

          -  Laboratory exclusions

          -  Hemoglobin &lt;7g/dL

          -  Total Bilirubin &lt;7.5mg/dL

          -  Aspartate aminotransferase (AST) &gt;500 IU/mL; or AST:Alanine aminotransferase (ALT)
             ratio &lt; 1

          -  Pregnant or breast-feeding or unwilling to use appropriate birth control

          -  Other clinically significant diseases (uncontrolled diabetes, severe cardiovascular or
             pulmonary disease, transplant recipient, recent cancer)

          -  Use of oral or systemic corticosteroids for more than 7 days during the 14 days prior
             to Day 1 or likely use of oral or systemic corticosteroids in the first 12 weeks of
             the clinical trial for underlying diseases

          -  Use of select contraindicated medications

          -  Previous randomization in the trial

          -  Based on the investigators judgment, subject is not capable of complying with the
             study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy R. Morgan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Long Beach Healthcare System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Long Beach Healthcare System</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LAC USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>July 16, 2013</study_first_submitted>
  <study_first_submitted_qc>July 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2013</study_first_posted>
  <results_first_submitted>September 20, 2018</results_first_submitted>
  <results_first_submitted_qc>October 19, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 25, 2018</results_first_posted>
  <last_update_submitted>December 26, 2018</last_update_submitted>
  <last_update_submitted_qc>December 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southern California Institute for Research and Education</investigator_affiliation>
    <investigator_full_name>Timothy Morgan, MD</investigator_full_name>
    <investigator_title>Chief, Hepatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Rilonacept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>4 participants were randomized. 3 in the standard of care (with Prednisolone) and 1 in mycophenolate + prednisolone arm. Out of 3 randomized to the SOC arm, 2 had a Lille score of &lt;.45 and one had a Lille score of &gt;.45. The participant who was randomized to mycophenolate + prednisolone had a Lille score of &gt;.45.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Continue Prednisolone (Lille &lt;0.45)</title>
          <description>Continue prednisolone 40 mg/day (current standard of care) for 21 days.
Prednisolone: Corticosteroid</description>
        </group>
        <group group_id="P2">
          <title>Rilonacept + Prednisolone (Lille &lt;0.45)</title>
          <description>Prednisolone (40mg/day) and rilonacept (Arcalyst®) subcutaneously once a week for 21 days (320 mg on study Day 8 and 160 mg on study Day 15 and study Day 22).
Rilonacept: Interleukin-1 blocker
Prednisolone: Corticosteroid</description>
        </group>
        <group group_id="P3">
          <title>Standard of Care (Lille ≥ 0.45)</title>
          <description>Standard of care therapy (continue prednisolone, stop all therapy and/or offer palliative care)</description>
        </group>
        <group group_id="P4">
          <title>Mycophenolate + Prednisolone (Lille ≥ 0.45)</title>
          <description>Prednisolone (40 mg/day) and mycophenolate mofetil for 21 days (500 mg BID for first 4 days followed by 1000 mg BID for the next 17 days).
Mycophenolate mofetil: Immunosuppressive agent
Prednisolone: Corticosteroid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>No participant was randomized to the Rilonacept + Prednisolone</population>
      <group_list>
        <group group_id="B1">
          <title>Continue Prednisolone (Lille &lt;0.45)</title>
          <description>Continue prednisolone 40 mg/day (current standard of care) for 21 days.
Prednisolone: Corticosteroid</description>
        </group>
        <group group_id="B2">
          <title>Rilonacept + Prednisolone (Lille &lt;0.45)</title>
          <description>Prednisolone (40mg/day) and rilonacept (Arcalyst®) subcutaneously once a week for 21 days (320 mg on study Day 8 and 160 mg on study Day 15 and study Day 22).
Rilonacept: Interleukin-1 blocker
Prednisolone: Corticosteroid</description>
        </group>
        <group group_id="B3">
          <title>Standard of Care (Lille ≥ 0.45)</title>
          <description>Standard of care therapy (continue prednisolone, stop all therapy and/or offer palliative care)</description>
        </group>
        <group group_id="B4">
          <title>Mycophenolate + Prednisolone (Lille ≥ 0.45)</title>
          <description>Prednisolone (40 mg/day) and mycophenolate mofetil for 21 days (500 mg BID for first 4 days followed by 1000 mg BID for the next 17 days).
Mycophenolate mofetil: Immunosuppressive agent
Prednisolone: Corticosteroid</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="1"/>
            <count group_id="B5" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.6" spread="9.7"/>
                    <measurement group_id="B3" value="71.2" spread="0"/>
                    <measurement group_id="B4" value="58" spread="0"/>
                    <measurement group_id="B5" value="52" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Survival at Day 29 of the Assigned Treatment</title>
        <description>To determine whether treatment with prednisolone + mycophenolate mofetil is better than standard of care treatment among patients with alcoholic hepatitis who fail to respond to 1 week of prednisolone (i.e., Lille score of ≥0.45). Primary outcome is survival at Day 29.
All study participants received the Standard of care (prednisolone) with or without experimental drug at Day 1 (based on randomization). Response to the treatment was determined at Day 8. Data was collected for both responders and non-responders.</description>
        <time_frame>Day 8 to Day 29</time_frame>
        <population>There was no participant randomized to rilonocept +prednisolone arm</population>
        <group_list>
          <group group_id="O1">
            <title>Continue Prednisolone (Lille &lt;0.45)</title>
            <description>Continue prednisolone 40 mg/day (current standard of care) for 21 days.
Prednisolone: Corticosteroid</description>
          </group>
          <group group_id="O2">
            <title>Rilonacept + Prednisolone (Lille &lt;0.45)</title>
            <description>Prednisolone (40mg/day) and rilonacept (Arcalyst®) subcutaneously once a week for 21 days (320 mg on study Day 8 and 160 mg on study Day 15 and study Day 22).
Rilonacept: Interleukin-1 blocker
Prednisolone: Corticosteroid</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care (Lille ≥ 0.45)</title>
            <description>Standard of care therapy (continue prednisolone, stop all therapy and/or offer palliative care)</description>
          </group>
          <group group_id="O4">
            <title>Mycophenolate + Prednisolone (Lille ≥ 0.45)</title>
            <description>Prednisolone (40 mg/day) and mycophenolate mofetil for 21 days (500 mg BID for first 4 days followed by 1000 mg BID for the next 17 days).
Mycophenolate mofetil: Immunosuppressive agent
Prednisolone: Corticosteroid</description>
          </group>
        </group_list>
        <measure>
          <title>Survival at Day 29 of the Assigned Treatment</title>
          <description>To determine whether treatment with prednisolone + mycophenolate mofetil is better than standard of care treatment among patients with alcoholic hepatitis who fail to respond to 1 week of prednisolone (i.e., Lille score of ≥0.45). Primary outcome is survival at Day 29.
All study participants received the Standard of care (prednisolone) with or without experimental drug at Day 1 (based on randomization). Response to the treatment was determined at Day 8. Data was collected for both responders and non-responders.</description>
          <population>There was no participant randomized to rilonocept +prednisolone arm</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Reported Ascites</title>
        <time_frame>Week 24</time_frame>
        <population>No patient was randomized to Rilonacept +prednisolone arm</population>
        <group_list>
          <group group_id="O1">
            <title>Continue Prednisolone (Lille &lt;0.45)</title>
            <description>Continue prednisolone 40 mg/day (current standard of care) for 21 days.
Prednisolone: Corticosteroid</description>
          </group>
          <group group_id="O2">
            <title>Rilonacept + Prednisolone (Lille &lt;0.45)</title>
            <description>Prednisolone (40mg/day) and rilonacept (Arcalyst®) subcutaneously once a week for 21 days (320 mg on study Day 8 and 160 mg on study Day 15 and study Day 22).
Rilonacept: Interleukin-1 blocker
Prednisolone: Corticosteroid</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care (Lille ≥ 0.45)</title>
            <description>Standard of care therapy (continue prednisolone, stop all therapy and/or offer palliative care)</description>
          </group>
          <group group_id="O4">
            <title>Mycophenolate + Prednisolone (Lille ≥ 0.45)</title>
            <description>Prednisolone (40 mg/day) and mycophenolate mofetil for 21 days (500 mg BID for first 4 days followed by 1000 mg BID for the next 17 days).
Mycophenolate mofetil: Immunosuppressive agent
Prednisolone: Corticosteroid</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Reported Ascites</title>
          <population>No patient was randomized to Rilonacept +prednisolone arm</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Continue Prednisolone (Lille &lt;0.45)</title>
          <description>Continue prednisolone 40 mg/day (current standard of care) for 21 days.
Prednisolone: Corticosteroid</description>
        </group>
        <group group_id="E2">
          <title>Rilonacept + Prednisolone (Lille &lt;0.45)</title>
          <description>Prednisolone (40mg/day) and rilonacept (Arcalyst®) subcutaneously once a week for 21 days (320 mg on study Day 8 and 160 mg on study Day 15 and study Day 22).
Rilonacept: Interleukin-1 blocker
Prednisolone: Corticosteroid</description>
        </group>
        <group group_id="E3">
          <title>Standard of Care (Lille ≥ 0.45)</title>
          <description>Standard of care therapy (continue prednisolone, stop all therapy and/or offer palliative care)</description>
        </group>
        <group group_id="E4">
          <title>Mycophenolate + Prednisolone (Lille ≥ 0.45)</title>
          <description>Prednisolone (40 mg/day) and mycophenolate mofetil for 21 days (500 mg BID for first 4 days followed by 1000 mg BID for the next 17 days).
Mycophenolate mofetil: Immunosuppressive agent
Prednisolone: Corticosteroid</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Rectal Bleeding</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Executive Director, Southern California Institute for Research and Education</name_or_title>
      <organization>SCIRE</organization>
      <phone>562-826-8000 ext 5747</phone>
      <email>Sabry.Eassa@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

